The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
332
Change From Baseline in Left Atrial Reservoir Strain (LARS) at Week 26
Results are estimated using least squares (LS) mean from the mixed model repeated measures (MMRM) model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26
Change From Baseline in Left Atrial Reservoir Strain (LARS) at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline in Log-transformed N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline in Log-transformed N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26
Change From Baseline in Left Atrial End-Diastolic Volume Index (LAEDVI) at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline in Left Atrial End-Diastolic Volume Index (LAEDVI) at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pima Heart
Tucson, Arizona, United States
Valley Clinical Trials, Inc.
Covina, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
University of California Irvine Medical Center
Orange, California, United States
Pasadena Clinical Research
Pasadena, California, United States
Velocity Clinical Research, Coastal Heart Medical Group
Santa Ana, California, United States
Excel Medical Clinical Trials
Boca Raton, Florida, United States
Infinite Clinical Research
Miami, Florida, United States
South Florida Research Solutions - North Flamingo Road
Pembroke Pines, Florida, United States
University Medical Center New Orleans
New Orleans, Louisiana, United States
...and 127 more locations
Time frame: Baseline, Week 26
Change From Baseline Left Atrial End-Systolic Volume Index (LAESVI) at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline Left Atrial End-Systolic Volume Index (LAESVI) at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment. The unit of measure for this outcome is millilitres per minute per 1.73 square metres (mL/min/1.73 m²)
Time frame: Baseline, Week 12
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26
Change From Baseline in Log-transformed Serum Creatinine at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline in Log-transformed Serum Creatinine at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26
Change From Baseline in Log-transformed Cystatin-C at Week 12
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 12
Change From Baseline in Log-transformed Cystatin-C at Week 26
Results are estimated using LS mean from the MMRM model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Time frame: Baseline, Week 26